The Medicines Company (NASDAQ:MDCO) Rating Changes as of Jun 27, 2018

June 27, 2018 - By Sarah Harris

The Medicines Company (NASDAQ:MDCO) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.02. That’s change of 0.23, from 2017Q4’s 1.25. 30 investors sold all, 51 reduced holdings as The Medicines Company ratio dropped. 58 rose positions while 25 funds bought positions. Funds hold 91.05 million shares thus 1.80% more from 2017Q4’s 89.44 million shares.
Westfield Capital Lp accumulated 3.03M shs. Profund Advsrs Ltd Liability Company holds 0.02% of its capital in The Medicines Company (NASDAQ:MDCO) for 14,146 shs. Illinois-based Balyasny Asset Management Ltd has invested 0.02% in The Medicines Company (NASDAQ:MDCO). Dekabank Deutsche Girozentrale reported 39,900 shs. Antipodean Advisors Limited Liability Com reported 237,500 shs. Creative Planning invested 0.01% in The Medicines Company (NASDAQ:MDCO). Nomura Incorporated holds 100 shs. Morgan Stanley holds 0% or 202,153 shs. Nelson Van Denburg And Campbell Wealth Mgmt Group Inc Inc Ltd Llc owns 4,630 shs or 0.04% of their US capital. Legal General Pcl invested 0% of its capital in The Medicines Company (NASDAQ:MDCO). Partner Fund Limited Partnership has invested 1.47% in The Medicines Company (NASDAQ:MDCO). State Board Of Administration Of Florida Retirement System has invested 0% in The Medicines Company (NASDAQ:MDCO). 7,000 were accumulated by Opus Point Management Limited Liability Corporation. Ameriprise Inc stated it has 516,781 shs or 0.01% of all its holdings. Hall Laurie J Trustee stated it has 0.02% of its capital in The Medicines Company (NASDAQ:MDCO).

The Medicines Company had 3 selling transactions and 0 insider purchases since January 16, 2018. This’s net activity of $1.06 million. 7,500 shs were sold by CROUSE WILLIAM, worth $241,950 on Wednesday, March 21. 7,500 The Medicines Company (NASDAQ:MDCO) shs with value of $241,500 were sold by Spigelman Melvin K.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

In total 4 analysts cover Medicines Co (NASDAQ:MDCO). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:MDCO)’s analyst reports since January 15, 2018 according to StockzIntelligence Inc. On Wednesday, June 6 the firm has “Buy” rating by FBR Capital given. On Monday, January 15 the firm has “Buy” rating by Oppenheimer given. On Thursday, March 22 the stock has “Buy” rating by Oppenheimer. On Thursday, February 22 the firm has “Hold” rating by Oppenheimer given. On Monday, January 22 the stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Citigroup. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

06/06/2018 Broker: FBR Capital Rating: Buy New Target: $55.0000 Initiate
22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain

The stock increased 1.12% or $0.4 during the last trading session, hitting $35.99.The Medicines Company has volume of 464,943 shares. Since June 27, 2017 MDCO has declined 16.45% and is downtrending. MDCO underperformed the S&P500 by 29.02%.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.65 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news posted recently go to: Seekingalpha.com, Investorplace.com, Seekingalpha.com, Streetinsider.com or Businesswire.com. The titles are as follows: “Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases” posted on June 06, 2018, “20 Massively Underpriced Stocks Wall Street Expects to Soar” on June 25, 2018, “Premarket analyst action – healthcare” with a publish date: June 07, 2018, “Medicines Co. (MDCO) Highlights New Data from ORION-1 Phase II Trial at ADA 2018 Conference” and the last “Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes” with publication date: June 26, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.